Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With Promoter Variant.
作者信息
Groisser Alissa, John Liny, Kirkorian A Yasmine, Gulino Sam P, Rossi Christopher T, Vyas Pranav K, Gagan Jeffrey, Raffeld Mark, Aldape Kenneth, Barr Frederic G, Xi Liqiang, Lee Ina, Ferrone Christina K, Pack Svetlana D, Kaplan Rosandra N, Goldstein Alisa M, Barnhill Raymond, Yohe Marielle, Sargen Michael R
机构信息
Division of Oncology, Children's National, Washington, DC.
Division of Dermatology, Children's National, Washington, DC.
出版信息
JCO Precis Oncol. 2025 Sep;9:e2500407. doi: 10.1200/PO-25-00407. Epub 2025 Sep 2.
Abstract
摘要
相似文献
1
Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With Promoter Variant.
JCO Precis Oncol. 2025 Sep;9:e2500407. doi: 10.1200/PO-25-00407. Epub 2025 Sep 2.
2
Atypical Spitz Tumor (Spitz Melanocytoma) With Lymph Node Metastasis and Long-Term Clinical Follow-Up.
Am J Dermatopathol. 2025 Jun 20;47(8):586-588. doi: 10.1097/DAD.0000000000002982.
3
A Clinical, Morphologic, and Molecular Comparison of Bonafide Spitz Melanomas and Atypical Spitz Tumors in the Pediatric Population.
Am J Surg Pathol. 2025 Jul 1;49(7):663-673. doi: 10.1097/PAS.0000000000002381. Epub 2025 Apr 24.
4
Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
J Cancer Res Clin Oncol. 2017 Apr;143(4):613-617. doi: 10.1007/s00432-016-2322-1. Epub 2016 Dec 18.
5
Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature.
Diagn Pathol. 2024 Oct 3;19(1):133. doi: 10.1186/s13000-024-01551-9.
6
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Cancer. 2004 Dec 1;101(11):2636-40. doi: 10.1002/cncr.20680.
7
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
Int J Cancer. 2022 Nov 1;151(9):1542-1554. doi: 10.1002/ijc.34187. Epub 2022 Jul 11.
8
Spitz melanoma is a distinct subset of spitzoid melanoma.
Mod Pathol. 2020 Jun;33(6):1122-1134. doi: 10.1038/s41379-019-0445-z. Epub 2020 Jan 3.
9
MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma.
Front Oncol. 2025 Jun 10;15:1585450. doi: 10.3389/fonc.2025.1585450. eCollection 2025.
10
A Stranger in the Slide: A Rare Collision of a Spitz Melanocytoma With a Novel MYH9::LTK Fusion and a Common BRAF Mutated Nevus Mimicking a Melanoma With a Preexistent Nevus.
Am J Dermatopathol. 2025 Jun 25. doi: 10.1097/DAD.0000000000003039.
本文引用的文献
1
Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series.
Pediatr Blood Cancer. 2025 Aug;72(8):e31814. doi: 10.1002/pbc.31814. Epub 2025 May 19.
2
A Clinical, Morphologic, and Molecular Comparison of Bonafide Spitz Melanomas and Atypical Spitz Tumors in the Pediatric Population.
Am J Surg Pathol. 2025 Jul 1;49(7):663-673. doi: 10.1097/PAS.0000000000002381. Epub 2025 Apr 24.
3
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.
J Clin Oncol. 2025 Mar 20;43(9):1157-1167. doi: 10.1200/JCO.24.01154. Epub 2024 Oct 4.
4
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
Eur J Cancer. 2024 Sep;208:114208. doi: 10.1016/j.ejca.2024.114208. Epub 2024 Jul 6.
5
CRTC1::TRIM11 cutaneous tumor: An update with local recurrence and lung metastasis in a pediatric patient.
J Cutan Pathol. 2024 Mar;51(3):181-183. doi: 10.1111/cup.14556. Epub 2023 Nov 9.
6
Association of germline variants in telomere maintenance genes ( and ) with spitzoid morphology in familial melanoma: A multi-center case series.
JAAD Int. 2023 Jan 30;11:43-51. doi: 10.1016/j.jdin.2023.01.013. eCollection 2023 Jun.
7
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Cancer. 2023 Jun 1;129(11):1723-1734. doi: 10.1002/cncr.34716. Epub 2023 Mar 4.
8
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Clin Cancer Res. 2022 Dec 1;28(23):5088-5097. doi: 10.1158/1078-0432.CCR-22-2164.
9
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.
Nat Immunol. 2022 May;23(5):660-670. doi: 10.1038/s41590-022-01141-1. Epub 2022 Mar 3.
10
Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
J Am Acad Dermatol. 2020 Sep;83(3):860-869. doi: 10.1016/j.jaad.2020.03.100. Epub 2020 Apr 10.
Zotero 插件